Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Conformationally constrained 6‑aryl‑1‑(3,4,5‑trimethoxyphenyl)-1H-pyrazolo[3,4‑b]pyrazines as novel microtubule destabilizers: design, synthesis, and antitumor evaluation.

Created on 20 Aug 2026

Authors

Zhu Guo, Yujing Zhang, Ping Zou, Caiyun Sun, Liya Cui, Gang Wang, Chao Wang

Published in

Journal of enzyme inhibition and medicinal chemistry. Volume 41. Issue 1. Pages 2717975. Epub Aug 20, 2026.

Abstract

A novel class of 6-aryl-1-(3,4,5-trimethoxyphenyl)-1H-pyrazolo[3,4-b]pyrazine derivatives was designed and synthesized as tubulin polymerization disruptors. Among them, compound 10t emerged as the most potent agent, exhibiting IC₅。 values of 0.13-0.18 µM against HeLa, SGC‑7901, and MCF‑7 cancer cell lines. Functional studies revealed that 10t effectively inhibits tubulin assembly in vitro, destabilizes cellular microtubule networks, induces G₂/M cell‑cycle arrest, and triggers apoptosis. Molecular docking indicated that 10t binds to the colchicine site on tubulin, forming a unique hydrogen bond with β‑Asn349 that is not observed with the reference compound CA‑4. Importantly, 10t showed significantly lower cytotoxicity toward normal HUVECs than CA‑4, suggesting an improved safety profile. Collectively, these findings establish the pyrazolo[3,4‑b]pyrazine scaffold as a promising platform for microtubule‑targeting anticancer agents and identify 10t as a compelling lead for further development.

PMID:
42621831
Bibliographic data and abstract were imported from PubMed on 20 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 0
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement